TEVA PHARMACEUTICAL INDUSTRIES LTD
For the period ended Mar 31, 2026. Filed Apr 29, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed Apr 29, 2026
TEVA$42.40-1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Income (loss)
(U.S. dollars in millions, except share and per share data)
| Three months endedMarch 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Net revenues | $3,982 | $3,891 |
| Cost of sales | 2,011 | 2,014 |
| Gross profit | 1,972 | 1,877 |
| Research and development expenses | 222 | 247 |
| Selling and marketing expenses | 696 | 622 |
| General and administrative expenses | 304 | 297 |
| Intangible assets impairments | 8 | 121 |
| Other assets impairments, restructuring and other items | 26 | (22) |
| Legal settlements and loss contingencies | 72 | 86 |
| Other loss (income) | (9) | 5 |
| Operating income (loss) | 652 | 519 |
| Financial expenses, net | 216 | 225 |
| Income (loss) before income taxes | 437 | 294 |
| Income taxes (benefit) | 67 | 74 |
| Share in (profits) losses of associated companies, net | 1 | * |
| Net income (loss) | 369 | 220 |
| Net income (loss) attributable to redeemable and non-redeemable non-controlling interests | * | 6 |
| Net income (loss) attributable to Teva | 369 | 214 |
| Earnings (loss) per share attributable to ordinary shareholders: | ||
| Basic | $0.32 | $0.19 |
| Diluted | $0.31 | $0.18 |
| Weighted average number of shares (in millions): | ||
| Basic | 1,156 | 1,138 |
| Diluted | 1,179 | 1,159 |
| * | Represents an amount less than $0.5 million. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.